F S&P 500
5,613.50 -8.00 (-0.14%) F Dow Jones
39,634.00 -61.00 (-0.15%) F Nasdaq
20,593.75 -27.00 (-0.13%) E-mini Russell 2000 Index Futur
2,039.90 -2.80 (-0.14%) Petróleo
82.78 -0.38 (-0.46%) Oro
2,393.90 -3.80 (-0.16%)
PROCEPT BioRobotics Corporation (PRCT)
Fuera de horario:
PROCEPT BioRobotics Corporation
150 Baytech Drive
San Jose, CA 95134
United States
650 232 7200
https://www.procept-biorobotics.com
Sector(es): Healthcare
Industria: Medical Devices
Empleados a tiempo completo: 626
Ejecutivos clave
| Nombre | Título | Pagar | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Dr. Reza Zadno Ph.D. | President, CEO & Director | 1.13M | 1.17M | 1955 |
| Mr. Kevin Waters | Executive VP & CFO | 680.11k | 3.1M | 1977 |
| Ms. Alaleh Nouri | EVP, Chief Legal Officer & Corporate Secretary | 605.84k | 1.63M | 1979 |
| Mr. Hisham Shiblaq | Executive VP & Chief Commercial Officer | 645.95k | N/D | 1976 |
| Mr. Mohan F. Sancheti | Senior Vice President of Operations | N/D | N/D | 1964 |
| Mr. Barry Templin | Executive VP of Technology & Clinical Development | N/D | N/D | N/D |
| Mr. Matthew James Bacso C.F.A. | Vice President of Investor Relations | N/D | N/D | N/D |
| Ms. Stacey L. Porter | Chief People Officer | N/D | N/D | 1976 |
| Mr. Bijesh Chandran | Senior Vice President of Regulatory Affairs & Quality Assurance | N/D | N/D | N/D |
Descripción
PROCEPT BioRobotics Corporation, a surgical robotics company, focuses on developing transformative solutions in urology in the United States and internationally. The company develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH). It also designs Aquablation therapy for males suffering from lower urinary tract symptoms due to BPH. PROCEPT BioRobotics Corporation was incorporated in 2007 and is headquartered in San Jose, California.
Gestión corporativa
La calificación ISS Governance QuickScore de PROCEPT BioRobotics Corporation a partir del 1 de julio de 2024 es 6. Las puntuaciones principales son Auditoría: 2; Junta: 5; Derechos del accionista: 8; Compensación: 8.
